Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01339871 · ClinicalTrials.gov registry record · Phase 1

Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

A Phase 1 study of Advanced Cancer, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
152
Enrollment target
1
Study location

NCT01339871 is a Phase 1 study of Advanced Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 152 participants, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01339871, a Phase 1 study of Advanced Cancer, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
152 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to find the highest tolerable dose of the combination of pazopanib and vorinostat that can be given to patients with advanced cancer. The safety of the drug combination will also be studied.

Conditions Studied

Advanced Cancer

Interventions

  • DRUG Vorinostat
  • DRUG Pazopanib

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2011-04-20
Est. Completion 2017-06-07
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01339871

The ClinicalTrials.gov registry entry for NCT01339871 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (38% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which Vorinostat is the first listed.

NCT01339871 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01339871 about?

NCT01339871 is a clinical study titled "Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies". The goal of this clinical research study is to find the highest tolerable dose of the combination of pazopanib and vorinostat that can be given to patients with advanced cancer. The safety of the drug combination will also be studied.

What is the current status of trial NCT01339871?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2011-04-20. Estimated completion is 2017-06-07.

What conditions does trial NCT01339871 study?

This clinical trial studies the following conditions: Advanced Cancer.

What interventions are being tested in trial NCT01339871?

The interventions under investigation include: Vorinostat (DRUG), Pazopanib (DRUG).

Who is sponsoring clinical trial NCT01339871?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01339871 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Cancer

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.